Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
for Sickle Cell Disease
Drug: Ruxolitinib
Sites in New Orleans +3 more locations
Sponsor: Arkansas Children's Hospital Research Institute
Sex: All·Age: 12 - 45
Code: NCT07252050·Phase 1, Phase 2·Recruiting·Listed Nov 2025